Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actimab-A and Cemiplimab in Recurrent Glioblastoma
NCT07422363Phase 1Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2026
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of lintuzumab satetraxetan ac-225 in glioblastoma (GBM), sponsored by National Cancer Institute. Primary endpoints: Dose limiting toxicities up to 6 weeks, Maximum tolerated dose up to 18 months and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
lintuzumab satetraxetan ac-225
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07422363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07422363.